NEW YORK, August 18, 2016 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com takes a closer look at these four equities: Illumina Inc. (NASDAQ: ILMN), XOMA Corp. (NASDAQ: XOMA), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and VIVUS Inc. (NASDAQ: VVUS). According to Morgan Stanley's Adam Parker, U.S. Biotech stocks are now trading at equal or lower valuations as U.S. and European pharmaceutical companies on price-to-forward earnings and at a slight discount on price-to-operating cash flow. Learn more about these stocks by downloading their comprehensive and free reports at:
On Wednesday, shares in San Diego, California headquartered Illumina Inc. recorded a trading volume of 922,623 shares. The stock ended the session 0.29% lower at $169.15. The Company's shares have gained 13.77% in the last one month and 20.62% in the previous three months. The stock is trading 12.64% above its 50-day moving average and 7.63% above its 200-day moving average. Moreover, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 63.88.
On July 27th, 2016, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with an increase of the target price from $138 a share to $148 a share.
On August 8th, 2016, Personal Genome Diagnostics Inc., a leading provider of advanced cancer genome testing products and services, announced an agreement with Illumina to develop two in-vitro diagnostic test kits for use on Illumina's sequencing instruments, including kits for the detection and characterization of tumor DNA using both tissue and plasma samples. ILMN complete research report is just a click away and free at:
Berkeley, California headquartered XOMA Corp.'s stock closed the day 1.55% lower at $0.60 and with a total volume of 487,997 shares traded. The Company's shares have advanced 19.12% in the past one month. The stock is trading 2.50% above its 50-day moving average. Additionally, shares of XOMA, which discovers, develops, and commercializes antibody-based therapeutics in the US, Europe, and the Asia Pacific, have an RSI of 49.65.
On August 4th, 2016, XOMA recorded total revenues of $0.4 million for the three months ended June 30th, 2016, compared to $2.5 million during the corresponding period of 2015. The decrease in Q2 2016 revenues was due primarily to decreased revenues from the National Institute of Allergy and Infectious Diseases and Servier. Research and development expenses for Q2 2016 were $13.7 million, compared with $19.7 million in the corresponding 2015 period. The complimentary report on XOMA can be downloaded at:
Shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. recorded a trading volume of 553,247 shares. The stock ended yesterday's trading session 0.77% lower at $15.53. The Company's shares have advanced 6.08% in the past one month, 23.75% in the previous three months, and 16.68% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.77% and 21.36%, respectively. Furthermore, shares of Lexicon Pharmaceuticals, which focuses on the discovery and development of pharmaceutical products for the treatment of human diseases, have an RSI of 49.24.
On August 4th, 2016, Lexicon Pharmaceuticals reported that revenues for the three months ended June 30th, 2016 increased to $20.1 million from $0.4 million for the corresponding period in 2015, primarily due to revenues recognized from the collaboration and license agreement with Sanofi. The company noted that net loss for the three months ended June 30th, 2016 was $38.1 million, or $0.37 per share, compared to a net loss of $28.1 million, or $0.27 per share, in the corresponding period in 2015.
On August 5th, 2016, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $30 a share to $31 a share. Sign up for your complimentary research report on LXRX at:
Mountain View, California headquartered VIVUS Inc.'s stock finished the session 0.94% lower at $1.05 with a total volume of 238,531 shares traded. The Company's shares have advanced 2.94% since the start of this year. The stock is trading below its 50-day moving averages by 6.78%. Additionally, shares of VIVUS, which develops and commercializes therapies to address unmet medical needs in the US and the European Union, have an RSI of 44.21.
On July 27th, 2016, VIVUS announced that it has filed a lawsuit against Hetero USA, Inc. and Hetero Labs Limited, collectively referred to as Hetero. The lawsuit was filed in response to an Abbreviated New Drug Application, filed by Hetero. In its application, Hetero seeks to market and sell generic versions of the currently approved doses of STENDRA® (avanafil) tablets prior to the expiration of U.S. Patents 6,656,935 and 7,501,409, which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Get free access to your research report on VVUS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA